Daniel Wechsler | President & Chief Executive Officer
Melinta Therapeutics Inc

Daniel Wechsler, President & Chief Executive Officer, Melinta Therapeutics Inc

Dan Wechsler joined Melinta as President and Chief Executive Officer in November 2017 and is a seasoned pharmaceutical executive with more than 25 years of healthcare experience across multiple companies and geographies, and a proven record of strategic, operational and commercial success. His notable antibiotics experience includes the commercialization of Zyvox (linezolid), an antibiotic that achieved blockbuster status. Mr. Wechsler started his career with The Upjohn Company selling antibiotics and other pharmaceutical products. He subsequently led the team at Pharmacia Corporation that launched Zyvox until the company’s acquisition by Pfizer. Mr. Wechsler has held senior positions at Pfizer Inc, Schering-Plough Corporation and Merck & Co. In 2010, Mr. Wechsler joined Bausch + Lomb Incorporated as executive vice president and global president of pharmaceuticals, where he led a greater than $1 billion global pharmaceutical business prior to the sale of the company to Valeant Pharmaceuticals for $8.7 billion. Most recently, Mr. Wechsler served as president and CEO of Smile Brands, Inc. until its sale in 2016, at which time he joined Welsh, Carson, Anderson & Stowe as an operating partner. He holds a master’s degree from the University of Rochester and a bachelor’s degree from the State University of New York at Brockport.


World Anti-Microbial Resistance Congress USA 2018 - Day 1 @ 08:55

Keynote address: Leading the industry in novel class antibiotics and stewardship initiatives – coordinated efforts in stewardship, diagnostics and drug development to fight resistance

  • Moving past commercial stage to conduct AMR surveillance through post marketing susceptibility testing and real-world evidence use registries
  • Economics of stewardship – evaluating economic models to support the responsible and sustainable use of antibiotics
  • Ensuring appropriate antibiotic use through coordinated educational efforts with providers
  • What next? How CARB-X funding is impacting Melinta’s pipeline of novel class antibiotics to further combat resistance

World Anti-Microbial Resistance Congress USA 2018 - Day 1 @ 17:30

Keynote CEO Panel: How to do business in a challenging environment - Current landscape for biotechs looking to commercialize or commercializing antimicrobials

  • How do you turn the current antibiotic development and commercialization model into one that is attractive to big pharma
  • Partnering and business development opportunities for smaller antibiotic biotechs – overcoming low stock prices
  • How can developing companies survive in this space and get continuous investments? Is the emergence of smaller companies the way to commercial viability and efficient distribution of resources
  • What is the investment landscape going to look like for up and coming companies
  • How to launch a product and demonstrate commercial success
last published: 19/Oct/18 16:35 GMT

back to speakers